Mizuho Has Lowered Expectations for Charles River Laboratories International (NYSE:CRL) Stock Price

Charles River Laboratories International (NYSE:CRL) had its price objective decreased by Mizuho from $175.00 to $155.00 in a report issued on Wednesday morning,Benzinga reports. Mizuho currently has a neutral rating on the medical research company’s stock.

CRL has been the topic of a number of other reports. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Barclays cut their price target on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a report on Tuesday, February 18th. The Goldman Sachs Group cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Finally, JPMorgan Chase & Co. cut their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $182.00.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $99.56 on Wednesday. The business has a 50-day moving average price of $156.71 and a 200-day moving average price of $177.01. The firm has a market cap of $4.89 billion, a price-to-earnings ratio of 663.71, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International has a twelve month low of $91.86 and a twelve month high of $254.15. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.46 EPS. As a group, equities research analysts predict that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is owned by corporate insiders.

Institutional Trading of Charles River Laboratories International

Large investors have recently made changes to their positions in the stock. EP Wealth Advisors LLC bought a new stake in Charles River Laboratories International during the 3rd quarter valued at about $273,000. National Bank of Canada FI raised its stake in shares of Charles River Laboratories International by 45.4% during the third quarter. National Bank of Canada FI now owns 21,216 shares of the medical research company’s stock valued at $4,179,000 after acquiring an additional 6,627 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its stake in shares of Charles River Laboratories International by 13.7% during the third quarter. Nomura Asset Management Co. Ltd. now owns 15,592 shares of the medical research company’s stock valued at $3,071,000 after acquiring an additional 1,882 shares in the last quarter. M&T Bank Corp boosted its holdings in shares of Charles River Laboratories International by 3.4% in the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock valued at $394,000 after purchasing an additional 66 shares during the period. Finally, Neo Ivy Capital Management bought a new position in Charles River Laboratories International in the third quarter worth approximately $966,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).